Over the course of 50 years, the GOG Foundation has evolved to become a leader among clinical trial groups studying gynecologic cancer.

The Gynecologic Oncology Group, the earliest version of today’s GOG Foundation, was founded in 1970 and housed within the American College of Obstetricians Gynecologists. It later became an independent nonprofit with the formation of a 501(c)(3), providing a corporate home for NCI-sponsored cooperative group clinical trials. Since then, the GOG developed into a large organization with a robust trial portfolio that enjoyed extensive support from the gynecologic cancer research community.


  • GOG-258 shows adjuvant chemo-radiation does not improve relapse free survival vs chemotherapy alone in women with stage III or IV endometrial cancer.
  • GOG-213 shows secondary cytoreduction did not improve overall survival in patients with recurrent platinum sensitive ovarian cancer treated with chemotherapy and bevacizumab.


  • Dr. Larry J. Copeland is elected President of the GOG Foundation.


  • GOG-240 shows improved survival when bevacizumab is added to chemotherapy for advanced cervical cancer.
  • The Gynecologic Oncology Group (GOG) is restructured into The GOG Foundation, Inc.


  • The GOG, in partnership with the National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group, forms a new 501(C)(3) after the National Clinical Trials Network is reorganized. This new entity, NRG Oncology Foundation, Inc., becomes the corporate home for NCI-funded trials.


  • GOG-0173 demonstrates that sentinel node biopsy is effective in select women with vulvar cancer.


  • GOG-0218 improves PFS when bevacizumab was added to frontline chemotherapy and continued as maintenance in patients with stage III/IV ovarian cancer.


  • The GOG grows to nearly 200 member institutions across the country.


  • GOG-0172 intraperitoneal chemotherapy improved PFS and OS in women with stage III optimally debulked ovarian cancer.


  • The Gynecologic Oncology Group is incorporated.


  • Dr. Philip J. DiSaia elected as GOG Group Chair.


  • By the turn of the century, the GOG had grown within the Cancer Therapy Evaluation Program (CTEP) and NCI portfolio to become a significant contributor in defining the standard of care in gynecologic oncology.


  • NCI issues alert that chemo-radiation should be considered for all patients with cervical cancer based on findings from GOG-85 (collaboration with SWOG) and four other randomized trials.


  • GOG-111 is a landmark study that led to incorporation of taxanes into frontline chemotherapy for advanced ovarian cancer.


  • The GOG Quality of Life Committee was formed and Protocol 9102 was first protocol with a primary endpoint of patient-reported effects of chemotherapy, paving the way for GOG’s continued dedication to improving the quality of life for our patients.


  • Hoskins et al publish The Influence of Cytoreductive Surgery on recurrence-free interval and Survival in small volume Stage III Epithelial Ovarian Cancer based on secondary analysis of GOG Protocol 52.


  • Dr. Robert Park is elected Group Chairman.


  • GOG-33 leads to surgical staging of endometrial cancer.


  • The first clinical publication of the GOG, the preliminary results of Pilot 1, surgical staging of endometrial cancer. By the end of the decade, a total of 40 manuscripts would be published.


  • The GOG grows to 34 institutions, covering about 4,000 new invasive cancers a year, with 23 protocols activated.


  • The Gynecologic Oncology Group (GOG) is founded and housed within the American College of Obstetricians and Gynecologists.

For a more comprehensive review of GOG’s history and research, download our book.